Showing results (241-250 of 288) with videos related to
Sort By:
Pageof 29
JACC. Cardiovascular Interventions|February 5, 2010
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)Martin B Leon, David E Kandzari, Eric L Eisenstein, et al.Journal of the American College of Cardiology|March 20, 2015
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionRobert W Yeh, Dean J Kereiakes, Philippe Gabriel Steg, et al.Archives of Internal Medicine|July 11, 2012
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practiceAmit P Amin, John A Spertus, David J Cohen, et al.Heart (British Cardiac Society)|August 6, 2018
Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patientsSaibal Kar, Ted Feldman, Atif Qasim, et al.Heart (British Cardiac Society)|March 8, 2013
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE ProgramVasim Farooq, Pascal Vranckx, Laura Mauri, et al.Circulation|January 19, 2005
Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stentsLaura Mauri, E John Orav, A James O'Malley, et al.The New England Journal of Medicine|April 1, 2014
A controlled trial of renal denervation for resistant hypertensionDeepak L Bhatt, David E Kandzari, William W O'Neill, et al.American Heart Journal|April 1, 2019
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trialGregory Y H Lip, Laura Mauri, Gilles Montalescot, et al.Journal of the American College of Cardiology|April 4, 2015
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trialGeorge L Bakris, Raymond R Townsend, John M Flack, et al.Journal of the American College of Cardiology|May 27, 2014
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3George L Bakris, Raymond R Townsend, Minglei Liu, et al.Pageof 29